A detailed history of Susquehanna International Group, LLP transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 238,417 shares of AVXL stock, worth $1.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
238,417
Previous 264,435 9.84%
Holding current value
$1.78 Million
Previous $1.12 Million 21.43%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.11 - $7.04 $106,933 - $183,166
-26,018 Reduced 9.84%
238,417 $1.35 Million
Q2 2024

Aug 15, 2024

SELL
$3.39 - $5.02 $127,548 - $188,877
-37,625 Reduced 12.46%
264,435 $1.12 Million
Q1 2024

May 07, 2024

SELL
$4.55 - $6.75 $1.91 Million - $2.83 Million
-419,293 Reduced 58.13%
302,060 $1.54 Million
Q4 2023

Feb 14, 2024

BUY
$5.04 - $9.95 $1.39 Million - $2.74 Million
275,440 Added 61.77%
721,353 $6.72 Million
Q3 2023

Nov 14, 2023

SELL
$6.55 - $9.37 $1.23 Million - $1.76 Million
-187,726 Reduced 29.63%
445,913 $2.92 Million
Q2 2023

Aug 11, 2023

BUY
$7.66 - $9.5 $190,312 - $236,027
24,845 Added 4.08%
633,639 $5.15 Million
Q1 2023

May 16, 2023

BUY
$8.32 - $11.75 $1.95 Million - $2.75 Million
233,906 Added 62.39%
608,794 $5.22 Million
Q4 2022

Feb 14, 2023

BUY
$7.65 - $14.43 $96,168 - $181,399
12,571 Added 3.47%
374,888 $3.47 Million
Q3 2022

Nov 14, 2022

BUY
$8.9 - $12.86 $722,324 - $1.04 Million
81,160 Added 28.87%
362,317 $3.74 Million
Q2 2022

Aug 15, 2022

BUY
$7.31 - $12.84 $6,279 - $11,029
859 Added 0.31%
281,157 $2.81 Million
Q1 2022

May 16, 2022

SELL
$9.74 - $17.69 $2.57 Million - $4.67 Million
-263,725 Reduced 48.48%
280,298 $3.45 Million
Q4 2021

Feb 14, 2022

BUY
$16.88 - $23.31 $875,059 - $1.21 Million
51,840 Added 10.53%
544,023 $9.43 Million
Q3 2021

Nov 15, 2021

SELL
$16.82 - $25.75 $3.26 Million - $4.99 Million
-193,833 Reduced 28.25%
492,183 $8.84 Million
Q2 2021

Aug 11, 2021

BUY
$10.16 - $28.86 $6.66 Million - $18.9 Million
655,260 Added 2130.51%
686,016 $15.7 Million
Q1 2021

May 17, 2021

SELL
$5.17 - $16.13 $572,965 - $1.79 Million
-110,825 Reduced 78.28%
30,756 $460,000
Q4 2020

Feb 16, 2021

SELL
$4.01 - $7.58 $655,041 - $1.24 Million
-163,352 Reduced 53.57%
141,581 $765,000
Q3 2020

Nov 16, 2020

BUY
$3.8 - $5.0 $331,470 - $436,145
87,229 Added 40.07%
304,933 $1.39 Million
Q2 2020

Aug 14, 2020

SELL
$2.62 - $5.2 $65,887 - $130,769
-25,148 Reduced 10.36%
217,704 $1.07 Million
Q1 2020

May 15, 2020

BUY
$2.38 - $5.81 $234,013 - $571,268
98,325 Added 68.03%
242,852 $765,000
Q4 2019

Feb 14, 2020

SELL
$2.31 - $3.14 $28,907 - $39,293
-12,514 Reduced 7.97%
144,527 $374,000
Q3 2019

Nov 14, 2019

SELL
$2.22 - $3.9 $180,967 - $317,916
-81,517 Reduced 34.17%
157,041 $496,000
Q2 2019

Aug 16, 2019

BUY
$2.75 - $3.7 $11,013 - $14,818
4,005 Added 1.71%
238,558 $803,000
Q2 2019

Aug 14, 2019

SELL
$2.75 - $3.7 $283,173 - $380,996
-102,972 Reduced 30.51%
234,553 $790,000
Q1 2019

May 15, 2019

BUY
$1.68 - $3.42 $357,147 - $727,050
212,588 Added 170.16%
337,525 $1.03 Million
Q4 2018

Feb 14, 2019

SELL
$1.25 - $2.75 $98,827 - $217,420
-79,062 Reduced 38.76%
124,937 $195,000
Q3 2018

Nov 14, 2018

BUY
$2.23 - $3.82 $60,965 - $104,434
27,339 Added 15.48%
203,999 $557,000
Q2 2018

Aug 14, 2018

BUY
$2.08 - $4.26 $212,528 - $435,274
102,177 Added 137.18%
176,660 $463,000
Q1 2018

May 15, 2018

SELL
$2.32 - $3.44 $440,530 - $653,200
-189,884 Reduced 71.83%
74,483 $206,000
Q4 2017

Feb 14, 2018

BUY
$3.12 - $4.94 $86,960 - $137,687
27,872 Added 11.79%
264,367 $851,000
Q3 2017

Nov 20, 2017

BUY
$3.42 - $4.87 $808,812 - $1.15 Million
236,495
236,495 $979,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $581M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.